Growing clinical evidence is beginning draw attention to the minimally invasive neurosurgical devices market. Although open craniotomy remains a standard approach, the use of less invasive techniques is steadily rising, particularly as study results continue to show outcome improvements in treating intracranial haemorrhages (ICHs) and brain tumours. As more clinical trials in the minimally invasive neurosurgery space are released and professional guidelines are updated, the market for these devices is expected to steadily grow in the coming years.
According to GlobalData’s forecast, the global minimally invasive neurosurgical devices market is projected to grow at a compound annual growth rate (CAGR) of 6% from 2024 to 2034. Disposable handpieces are expected to grow at a CAGR of 10%, led by side-cutting aspiration disposable handpieces, at a CAGR of 16%. Subcortical access devices are projected to increase at a CAGR of 14%. Ultrasonic aspiration disposable tips are currently the largest device type category by market value, at around twice the size of the disposable handpiece segment in 2024.
Go deeper with GlobalData
Access deeper industry intelligence
Experience unmatched clarity with a single platform that combines unique data, AI, and human expertise.
North America is forecast to record the strongest growth during the period, followed by Asia-Pacific (APAC). Stryker Corp currently holds the largest global market share and leads in North America, South Central America and Europe. APAC and the Middle East and Africa are currently dominated by various medical device companies, although Stryker Corp also holds a substantial share in those regions.
Reimbursement remains a key consideration for market growth. Following the publication of favourable trial results, devices used in minimally invasive neurosurgery are expected to receive a higher incidence of government reimbursement. However, without reimbursement, the high cost of disposable components such as handpieces, tips and access devices can limit their use, particularly in cost-sensitive markets. In some developing regions, these components are sometimes reprocessed and reused to reduce expenses.
Currently, treatments for ICH range from medication and supportive care to conventional open surgery. Among minimally invasive options, ultrasonic aspiration systems are the most established and are viewed by key opinion leaders (KOLs) as the current standard for minimally invasive surgeries. Their broad applicability and proven safety record have supported their continued use. KOLs also indicate that continued clinical trial outcomes will likely encourage the wider adoption of minimally invasive neurosurgery devices.
As clinical trial results are released and government reimbursement frameworks improve, the minimally invasive neurosurgical devices market is positioned for substantial growth.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalData
